drugset / Trial / NCT00687011

Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)

NCT00687011

Phase 4 Completed 118 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron 0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and vomiting induced by moderately emetogenic chemotherapy in subjects with cancer.

Timeline

Start
2006-10-10
Primary completion
2008-10-27
Completion
2008-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 8 mg Intravenous
Subject Dexamethasone Small molecule 20 mg Intravenous
Subject Palonosetron Other / unclassified 0.25 mg Intravenous
Background Methylprednisolone Other / unclassified 125 mg Intravenous

Indications